Coya Therapeutics, Inc. (NASDAQ:COYA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have earned a consensus recommendation of “Moderate Buy” from the seven research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $15.3333.

Several research firms have issued reports on COYA. Roth Capital assumed coverage on Coya Therapeutics in a research note on Friday, June 5th. They issued a “buy” rating and a $12.00 price objective on the stock. Chardan Capital reiterated a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research note on Friday, June 12th. Wall Street Zen lowered Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. D. Boral Capital restated a “buy” rating and issued a $15.00 price target on shares of Coya Therapeutics in a research note on Friday, April 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Friday, July 17th.

Hedge Funds Weigh In On Coya Therapeutics

Several large investors have recently modified their holdings of COYA. Renaissance Technologies LLC lifted its stake in shares of Coya Therapeutics by 92.2% during the 4th quarter. Renaissance Technologies LLC now owns 66,900 shares of the company’s stock worth $388,000 after buying an additional 32,100 shares during the last quarter. Squarepoint Ops LLC acquired a new position in Coya Therapeutics in the 4th quarter valued at about $378,000. Citadel Advisors LLC grew its stake in Coya Therapeutics by 51.3% in the 3rd quarter. Citadel Advisors LLC now owns 65,240 shares of the company’s stock valued at $372,000 after buying an additional 22,120 shares during the last quarter. Walleye Capital LLC bought a new position in Coya Therapeutics in the 4th quarter valued at about $215,000. Finally, XTX Topco Ltd bought a new position in Coya Therapeutics in the 4th quarter valued at about $192,000. 39.75% of the stock is owned by institutional investors.

Coya Therapeutics Price Performance

Coya Therapeutics stock opened at $4.25 on Monday. The company’s 50-day moving average is $4.95 and its 200-day moving average is $4.69. The firm has a market capitalization of $99.70 million, a PE ratio of -3.70 and a beta of 0.51. Coya Therapeutics has a fifty-two week low of $3.71 and a fifty-two week high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Tuesday, May 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.07. Coya Therapeutics had a negative net margin of 266.10% and a negative return on equity of 55.86%. The business had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.15 million. As a group, analysts expect that Coya Therapeutics will post -1.49 EPS for the current year.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.